April 3, 2019 – DiaSorin (FTSE MIB: DIA) announced the launch in the CE market of the Vitamin B12 and Folate tests for the diagnosis and treatment of anaemia.

The new tests, in addition to the Ferritin test already in our menu, expand DiaSorin’s offer on the XL analyzer contributing to the creation of a new panel for anaemia diagnosis.

Anaemia is a disease characterized by an inadequate number of red blood cells and an insufficient level of hemoglobin, which prevents us from adequately supplying the oxygen tissues they need.

There are several types of anaemia, including iron deficiency anaemia, linked to low ferritin values, and vitamin deficiency anaemia, linked to vitamin B12 and folate deficiency.

Anaemia is estimated to affect 25% of the world’s population, mainly in South East Asia with a high prevalence in pre-school age children and women, especially if pregnant. Malnutrition and disorders in gastrointestinal absorption are among the main causes of this disease.

"I am particularly proud of the launch of the Vitamin B12 and Folate tests that allow us to enrich our offer in Europe with a new test panel for anaemia diagnosis," commented Carlo Rosa, CEO of the DiaSorin Group. "The development of new products and entrance into new clinical areas, one of the pillars of our growth, will continue to be one of the main drivers of our development also in the future."

DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years, the Company has been developing, producing and marketing reagent kits for IVD worldwide. The Group has a presence on the 5 continents with 25 companies, 5 foreign branches, 6 manufacturing facilities and 5 research centers throughout the world. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the “Diagnostic Specialist”.

For additional information, please contact:

Riccardo Fava  
Investor Relations & Corporate Communication Senior Director  
Tel: +39.0161.487988  
riccardo.fava@diasorin.it

Ines Di Terlizzi  
Investor Relator  
Tel: +39.0161.487567  
ines.diterlizzi@diasorin.it